Navigation Links
SURPASS Announces Two Strategic Hires in Silicon Valley Facility and Launch of Social Media Accounts
Date:7/17/2014

OSCEOLA, Wis. and MOUNTAIN VIEW, Calif., July 17, 2014 /PRNewswire-iReach/ -- Surpass, Inc. ("Surpass"), a recognized leader in translational preclinical research, today announced the addition of David Craig, a veteran preclinical scientist and expert veterinary interventionalist, and Benigno Mills, a veterinary surgical and interventional specialist, to the Surpass-Silicon Valley Team. In addition, to better serve our clients, we are pleased to announce that Surpass has launched social media accounts on Twitter, Facebook and Google+ to supplement the existing account on Linked In.

Photo - http://photos.prnewswire.com/prnh/20140717/128042

"Surpass is an integrated medical innovation partner for clients in the life-sciences community.  These recent strategic hires are evidence of Surpass' commitment to meet our clients' ever-changing needs - rounding out the Scientific and Veterinary Research Team at our West Coast site. With budgets getting tighter and timelines shorter, clients are looking for their CRO partners to do more. They want expertise in study conduct, execution, and reporting while offering flexibility in a compliant environment. The Surpass team offers customized service at our Midwest and West Coast facilities with expert professionals in surgical and interventional services," said Dr. Tim Pelura, President and CEO of Surpass.

David Craig, BS, Director of Operations and Interventional Services, comes to Surpass with more than 17 years of preclinical research experience, working at multiple domestic and international CROs and large medical device and pharmaceutical companies. Benigno Mills, BS, SRS, Interventional and Surgical Specialist, comes with more than five years of preclinical experience at a local contract research organization.

In addition to the recent hires, Surpass is pleased to announce the expansion of our social media platform to include Twitter, Facebook and Google+. "The world of corporate communications has changed.  As a valued partner, we want to connect with our clients where they are, on Twitter, Facebook and Google Plus in addition to Linked In. We want to provide value and insight for making their jobs easier," said Dr. Pelura.

About Surpass

Our innovative approach to preclinical research goes beyond the ordinary. We're changing the rules for a better way to get from concept to reality.

Surpass is a trusted contract research organization (CRO) with extensive experience conducting medical device, pharmaceutical, biotech and combination product studies with specialized expertise in surgical and interventional procedures. Our testing services include early feasibility, product development, GLP, and physician/clinical training studies. At Surpass, we provide insightful solutions and support every step of the way, offering expert advice and the level of comprehensive support needed to make your study successful – the first time.

Surpass' breadth of case experience in preclinical studies includes feasibility and safety assessments of ablation systems, vascular grafts, orthopedic prostheses, stents, closure devices, valves, infusion pumps, drug coated balloons, neurostimulators, pharmaceuticals, biologics, imaging systems, cardiac assist devices, and more. Whether you are a startup or an established player, Surpass is uniquely qualified to make your study successful. Contact Surpass today at (651) 433-4277 (Greater Twin Cities) or (650) 477-8267 (Silicon Valley).

Visit www.surpassinc.com for more information. Connect with Surpass, Inc. on Linked In, Twitter, Facebook, and Google+.

Media Contact: Denise Forkey, Surpass, Inc., 650-938-2101, dforkey@surpassinc.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Surpass, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. JCB Laboratories Debuts High Tech Monitoring System That Will Further Enhance Patient Safety, Surpass Compounding Pharmacy Standards
2. French Man Surpasses Two Years of Support with SynCardia Total Artificial Heart
3. SynCardia Total Artificial Heart Surpasses 100th Implant of 2013
4. Global Ubiquitin Proteasome Research and Development Market to Surpass $5.5 Billion by 2018: BCC Research
5. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
6. University of Oklahoma Housing and Food Likely to Surpass Budget, My Cleaning Products Recommends Pest Control Products That Could the Department's Spending in Half
7. Lucintel’s Analysis of Growth Opportunities in China’s Composites Industry: Expect Market to Surpass $11 Billion in 2017
8. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
9. Accuray Surpasses 600 Installations Globally
10. Pure Energy Group Announces Affiliation with American Biogas Council
11. Roka Bioscience Announces Pricing of Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
(Date:3/23/2017)... 23, 2017  Agriculture technology company Cool Planet has ... note conversion to commercialize its Cool Terra and Cool ... developing products that are simultaneously profitable as well as ... last 18 months. This latest round of funding was ... The company,s primary product, Cool Terra, ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)... March 22, 2017  UBM and the Massachusetts ... their extended partnership and the third annual Massachusetts Medtech ... the 21 st Annual MassMEDIC Conference held ... May 3-4, 2017. MassMEDIC will ... (ADVAMED) President and CEO, Scott Whitaker , ...
Breaking Biology Technology:
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft ... 8.8% over the next decade to reach approximately $14.21 billion by ... and forecasts for all the given segments on global as well ...
(Date:3/20/2017)... , March 20, 2017 At this year,s CeBIT ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together ... is this year,s CeBIT partner country. At the largest German biometrics company ... use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... Australia , March 9, 2017 ... the prestigious World Lung Imaging Workshop at the University ... , was invited to deliver the latest data to ... globally recognised event brings together leaders at the forefront ... developments in lung imaging. "The quality ...
Breaking Biology News(10 mins):